Drug intelligence / Profile preview

Astaper

Development stage: Unknown
Lead developer: Isfahan University of Medical Sciences
Modality: Small Molecules
Administration: Oral

Overview

Astaper is a brand name for a dietary supplement containing 10 mg of astaxanthin, a natural lipid-soluble keto-carotenoid. It is manufactured by the Zyest Technology Tarawat Zendig institute in Iran and has been investigated in clinical trials led by the Isfahan University of Medical Sciences. Astaxanthin acts as a potent antioxidant and anti-inflammatory agent by modulating the Nrf2 axis and reducing endoplasmic reticulum (ER) stress and inflammatory pathways. The supplement is being studied for its potential to improve clinical symptoms, cardio-metabolic profiles, insulin sensitivity, lipid profiles, and depression in women with Polycystic Ovary Syndrome (PCOS).

Brand names: Astaper
Other names: astaxanthin

Targets

NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)

Beyond the preview

Go deeper on Astaper.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Astaper.

Explore the full profile